Single-center prospective experience with Optilume® drug-coated balloon for recurrent urethral strictures: preliminary functional and safety outcomes
International Urology and Nephrology · 2025
DOI: 10.1007/s11255-025-04922-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Urology and Nephrology, 2025. Verfasst von Antonio Cretì und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Fondazione Policlinico Agostino Gemelli IRCSS, Largo Agostino Gemelli 1, 00167, Rome, Italy. antoniocreti@icloud.com. Hauptthemen laut MEDLINE: Urethral Stricture, Paclitaxel, Dilatation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università Cattolica del Sacro Cuore.
Abstract (Originalsprache)
Background
Urethral stricture disease remains a challenging condition in urology, particularly in cases with recurrent anterior urethral narrowing following prior endoscopic treatments. Traditional options such as dilation and direct vision internal urethrotomy (DVIU) are limited by high failure rates. The Optilume ® drug-coated balloon (DCB) delivers mechanical dilation combined with localized paclitaxel delivery, aiming to reduce restenosis and improve durability.
Objective
To evaluate the short-term functional outcomes and safety of Optilume ® DCB in patients with recurrent urethral strictures. Design, setting, and participants This was a prospective single-center study including 35 male patients with anterior urethral strictures ≤ 3 cm and at least one prior endoscopic treatment. Outcomes were assessed at 1, 3, and 6 months post-procedure. Outcome measurements and statistical analysis Primary outcomes included changes in Qmax (uroflowmetry), post-void residual (PVR), IPSS, and erectile function (IIEF-5). Recurrence was defined as symptomatic deterioration, Qmax < 10 mL/s, or need for retreatment. Paired t-tests were used for pre- and post-treatment comparisons, with p < 0.05 considered statistically significant. As this was an exploratory pilot study, no formal sample size calculation was performed; analyses were descriptive and hypothesis-generating. Results and limitations Mean Qmax improved from 10.2 ± 4.9 to 21.6 ± 3.1 mL/s (p < 0.001), and PVR decreased from 74.6 ± 36.3 to 24.8 ± 16.0 mL (p < 0.001). IPSS improved from 21.8 ± 4.8 to 8.7 ± 2.0 (p < 0.0001), and IIEF-5 scores increased from 13.7 ± 7.7 to 18.5 ± 7.6 (p = 0.012). The recurrence rate at 6 months was 8.6% (3/35). Minor adverse events included transient hematuria and dysuria. No Clavien-Dindo grade ≥ 2 complications were recorded. Study limitations include its single-arm, non-randomized design and relatively short follow-up, limiting direct comparison with DVIU, urethroplasty, or emerging minimally invasive surgical therapies (MISTs).
Conclusions
Optilume ® DCB treatment demonstrated significant improvements in urinary flow and symptoms with a low recurrence and complication rate at 6 months. It may serve as a minimally invasive alternative for patients unsuitable or unwilling to undergo urethroplasty. Further prospective evaluation is warranted, including its potential role in bladder neck sclerosis and benign prostatic obstruction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Fondazione Policlinico Agostino Gemelli IRCSS, Largo Agostino Gemelli 1, 00167, Rome, Italy. antoniocreti@icloud.com.
- Department of Urology, Fondazione Policlinico Agostino Gemelli IRCSS, Largo Agostino Gemelli 1, 00167, Rome, Italy.
- Department of Life Science, Health, and Health Professions, Rome, Italy.
- Department of Urology, C.Ur.E.-Centro Urologico Europeo, Mater Olbia Hospital, Olbia, OT, Italy.
Förderung
- Università Cattolica del Sacro Cuore
Zitieren
APA
Cretì, A., Ragonese, M., Russo, P., Foschi, N., Filomena, G. B., Silvestri, A., Fantasia, F., Cavarra, V., Scarciglia, E., Bizzarri, F. P., Sighinolfi, M., Rocco, B. M. C., & Pinto, F. (2025). Single-center prospective experience with Optilume® drug-coated balloon for recurrent urethral strictures: preliminary functional and safety outcomes. International Urology and Nephrology. https://doi.org/10.1007/s11255-025-04922-3
Vancouver
Cretì A, Ragonese M, Russo P, Foschi N, Filomena GB, Silvestri A, et al. Single-center prospective experience with Optilume® drug-coated balloon for recurrent urethral strictures: preliminary functional and safety outcomes. International Urology and Nephrology. 2025. doi:10.1007/s11255-025-04922-3
BibTeX
@article{Cret2025,
author = {Cretì, Antonio and Ragonese, Mauro and Russo, Pierluigi and Foschi, Nazario and Filomena, Giovanni Battista and Silvestri, Antonio and Fantasia, Fabrizio and Cavarra, Vincenzo and Scarciglia, Eros and Bizzarri, Francesco Pio and Sighinolfi, Mariachiara and Rocco, Bernardo Maria Cesare and Pinto, Francesco},
title = {Single-center prospective experience with Optilume® drug-coated balloon for recurrent urethral strictures: preliminary functional and safety outcomes},
journal = {International Urology and Nephrology},
year = {2025},
doi = {10.1007/s11255-025-04922-3}
}
EUVIMED